Gene therapy offers hope for rare blindness
NCT ID NCT07054632
First seen Mar 10, 2026 · Last updated May 17, 2026 · Updated 7 times
Summary
This study tests a gene therapy called LX101 for people with a rare inherited eye disease that causes blindness. 30 participants aged 6 and older were randomly assigned to receive the therapy or no treatment. The goal is to see if the treatment improves functional vision and light sensitivity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DYSTROPHY ASSOCIATED WITH RPE65 MUTATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital
Shanghai, China
-
Southwest Hospital of AMU
Chongqing, China
-
Tianjin Medical University Ophthalmology Hospital
Tianjin, China
-
Zhongshan Ophthalmic Center, Sun Yat sen University
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.